We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $881M
1-Year Est. Return 160.77%
This Fund
S&P 500
This Quarter Est. Return
+52.92%
1 Year Est. Return
+160.77%
3 Year Est. Return
+483.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$662M
AUM Growth
+$141M
Cap. Flow
-$4.74M
Cap. Flow %
-0.72%
Top 10 Hldgs %
99.6%
Holding
13
New
–
Increased
–
Reduced
–
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$4.52M
2
SPRO icon
Spero Therapeutics
SPRO
+$220K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$9.85B
$214M 32.26%
4,896,462
– –
IRON icon
2
Disc Medicine
IRON
$2.66B
$126M 19.07%
2,384,456
– –
DYN icon
3
Dyne Therapeutics
DYN
$3.37B
$86.9M 13.12%
9,130,465
– –
SION
4
Sionna Therapeutics
SION
$325M
$64.1M 9.68%
3,694,020
– –
THRD
5
DELISTED
Third Harmonic Bio
THRD
$56.5M 8.53%
10,402,286
– –
VIGL
6
DELISTED
Vigil Neuroscience
VIGL
$46.4M 7.01%
5,836,874
– –
DAWN
7
DELISTED
Day One Biopharmaceuticals
DAWN
$41.8M 6.31%
6,430,257
– –
KRRO icon
8
Korro Bio
KRRO
$174M
$14.2M 2.14%
1,137,149
– –
IMA
9
ImageneBio Inc
IMA
$57M
$6.72M 1.02%
418,182
– –
QTTB icon
10
Q32 Bio
QTTB
$323M
$3.12M 0.47%
2,092,106
– –
GBIO
11
DELISTED
Generation Bio
GBIO
$2.65M 0.4%
827,948
– –
JBIO
12
Jade Biosciences
JBIO
$1.09B
– –
-51,407
Closed -$4.52M
SPRO icon
13
Spero Therapeutics
SPRO
$65.2M
– –
-305,255
Closed -$220K

Similar funds

AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
FSCM
Front Street Capital Management Missoula, Montana $881M AUM 86.5% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $882M AUM 62.77% 1-Year Est. Return
TAM
TCP Asset Management Columbus, Ohio $882M AUM 21.79% 1-Year Est. Return
FFG
Fiduciary Financial Group San Rafael, California $882M AUM 23.98% 1-Year Est. Return
MWA
Meridian Wealth Advisors Austin, Texas $880M AUM 30.15% 1-Year Est. Return
1IA
1834 Investment Advisors Milwaukee, Wisconsin $883M AUM 23.82% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $880M AUM 44.18% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Atlas Venture Life Science Advisors held 13 positions worth $662M, up 27% from $522M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Life Science Advisors's Q2 2025 filing shows 2 closed positions. The largest sale was Jade Biosciences, an estimated $4.52M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors fully exited Jade Biosciences in Q2 2025, selling an estimated $4.52M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 100% of its $662M portfolio in Q2 2025.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 2 in Q2 2025.
  • Atlas Venture Life Science Advisors's portfolio value rose 27% quarter-over-quarter to $662M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.